Evidence map›Paper›PMID 38462672›Full record

SynthesisThe Journal of infectious diseases2024

Effect of Pneumococcal Conjugate Vaccines on Viral Respiratory Infections: A Systematic Literature Review.

Ingrid T Sepúlveda-Pachón, Eileen M Dunne, Germaine Hanquet, Marc Baay, Sonia Menon, Luis Jodar, Bradford D Gessner, Christian Theilacker

Abstract readSystematic Review
In one paragraph

Synthesis in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ingrid T Sepúlveda-PachónEpidemiology Department, P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Eileen M DunneGlobal Vaccines and Antivirals, Pfizer Inc, Collegeville, Pennsylvania.ORCID 0000-0001-5542-0780
Germaine HanquetEpidemiology Department, P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.ORCID 0000-0002-3382-0211
Marc BaayEpidemiology Department, P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.ORCID 0000-0001-7266-551X
Sonia MenonEpidemiology Department, P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.ORCID 0000-0002-4422-1185
Luis JodarGlobal Vaccines and Antivirals, Pfizer Inc, Collegeville, Pennsylvania.ORCID 0000-0003-1246-530X
Bradford D GessnerGlobal Vaccines and Antivirals, Pfizer Inc, Collegeville, Pennsylvania.ORCID 0000-0002-6216-7194
Christian TheilackerGlobal Vaccines and Antivirals, Pfizer Inc, Collegeville, Pennsylvania.ORCID 0000-0003-0821-9202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn addition to preventing pneumococcal disease, emerging evidence indicates that pneumococcal conjugate vaccines (PCVs) might indirectly reduce viral respiratory tract infections (RTIs) by affecting pneumococcal-viral interactions.

methodsWe performed a systematic review of interventional and observational studies published during 2000-2022 on vaccine efficacy/adjusted effectiveness (VE) and overall effect of PCV7, PCV9, PCV10, or PCV13 against viral RTIs.

resultsSixteen of 1671 records identified were included. Thirteen publications described effects of PCVs against viral RTIs in children. VE against influenza ranged between 41% and 86% (n = 4), except for the 2010-2011 influenza season. In a randomized controlled trial, PCV9 displayed efficacy against any viral RTI, human seasonal coronavirus, parainfluenza, and human metapneumovirus. Data in adults were limited (n = 3). PCV13 VE was 4%-25% against viral lower RTI, 32%-35% against coronavirus disease 2019 outcomes, 24%-51% against human seasonal coronavirus, and 13%-36% against influenza A lower RTI, with some 95% confidence intervals spanning zero. No protection was found against adenovirus or rhinovirus in children or adults.

conclusionsPCVs were associated with protection against some viral RTI, with the strongest evidence for influenza in children. Limited evidence for adults was generally consistent with pediatric data. Restricting public health evaluations to confirmed pneumococcal outcomes may underestimate the full impact of PCVs.

Indexed as

Pneumococcal VaccinesRespiratory Tract InfectionsVaccines, ConjugateAdultChildChild, PreschoolHumansInfantInfluenza, HumanPneumococcal InfectionsVaccine EfficacyVirus DiseasesPneumococcal VaccinesVaccines, Conjugatelower tract respiratory infectionLRTIpneumococcal conjugate vaccinepneumoniaviral

Identifiers

PMID38462672
PMCPMC11420806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.